Pfizer: Xtandi Reduces Risk Of Death By 34% In Men With Metastatic Hormone-Sensitive Prostate Cancer

Astellas Pharma Inc. and Pfizer Inc.'s (PFE) Xtandi or enzalutamide improved overall survival in men with metastatic hormone-sensitive prostate cancer, as per a phase 3 ARCHES Study.

The Phase 3, randomized, double-blind, placebo-controlled trial compared Xtandi plus androgen deprivation therapy versus placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer and overall survival was a key secondary endpoint.

In the study, Xtandi plus ADT reduced the risk of death by 34% compared to placebo plus androgen deprivation therapy. Median overall survival, which represents the time from randomization to death due to any cause, was not reached in either treatment group. The safety profile in both study arms was consistent with findings from the primary analysis.

The companies jointly commercialize Xtandi in the United States and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the United States.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
HSBC Holdings Plc shares were gaining In London trading as well as in pre-market activity on the NYSE after the Asia-focused lender backed its positive outlook after reporting significantly higher third-quarter profit. Further, the company announced share buyback of $2 billion, which will be commenced shortly. Walmart is recalling certain Aromatherapy Room Spray due to the possible presence of a rare and dangerous bacteria that is suspected to be behind two deaths in the United States, the U.S. Consumer Product Safety Commission said. The recall involves about 3,900 bottles of Better Homes and Gardens-branded Essential Oil Infused Aromatherapy Room Spray with Gemstones in six different scents. Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port.
Follow RTT